Rona Therapeutics Completes First Cohort of Phase 1 Trial for Novel INHBE-Targeting siRNA Obesity Treatment
核心洞察
Rona Therapeutics (搜索) successfully completed Cohort 1 dosing of RN3161 (搜索), a GalNAc-conjugated siRNA targeting INHBE, in its first-in-human Phase 1 clinical study for obesity treatment.
The investigational therapy demonstrated a favorable initial safety and tolerability profile, marking the first clinical milestone for Rona's INHBE program.
RN3161 (搜索) is designed for deep and durable INHBE silencing with once- or twice-yearly dosing, offering a differentiated therapeutic approach for obesity treatment.
Rona Therapeutics (搜索), a clinical-stage RNAi company, has successfully completed the first cohort dosing in its Phase 1 first-in-human clinical study of RN3161 (搜索), an investigational GalNAc-conjugated siRNA targeting INHBE for obesity treatment. The completion of Cohort 1 with a favorable initial safety and tolerability profile represents the first clinical milestone for the company's INHBE program.
Novel Therapeutic Approach for Obesity
RN3161 (搜索) is designed to achieve deep and durable silencing of INHBE with once- or twice-yearly dosing, potentially offering a differentiated therapeutic profile for obesity treatment. Scientific and industry interest in INHBE has accelerated, supported by compelling human genetic evidence and emerging clinical observations, according to the company.
"We are pleased to report successful completion of our first cohort in this Phase 1 trial, an important step in advancing RN3161 (搜索) and validating the potential of INHBE as a new metabolic target," said Alex M. DePaoli, MD, Chief Medical Officer at Rona Therapeutics (搜索). "This milestone underscores the strength of our siRNA therapeutic platform as we work to bring forward next-generation siRNAs for metabolic disease."
Phase 1 Study Design and Timeline
The ongoing Phase 1 study is structured as a randomized, double-blind, placebo-controlled trial designed to evaluate multiple parameters in adults with overweight and obesity. The study's primary objectives include assessing safety, tolerability, pharmacokinetics, pharmacodynamics, and effects on body weight.
Additional cohorts are planned for completion throughout 2026, as the company continues to advance this novel approach to obesity treatment through clinical development.
Company Background and Platform
Rona Therapeutics (搜索), established in 2021, positions itself as a world-leading RNAi therapeutics company focused on addressing cardiometabolic, obesity, and degenerative diseases through its next-generation RNA technology platform. The company has progressed four programs into clinical development, leveraging its proprietary platform encompassing delivery, multi-valency, and oligonucleotide chemistry innovations.
The company has secured approximately $200 million in funding from global healthcare investors and strategic partners, supporting its clinical development programs and platform advancement.